Dopaminergic neurons of the putamen

The dopaminergic neuron population in the putamen refers to the axonal terminals of neurons originating in the substantia nigra pars compacta (SNc), which together form the nigrostriatal pathway. These neurons are essential for the regulation of motor functions and the execution of voluntary movements by releasing dopamine into the putamen, a key component of the basal ganglia (StatPearls, 2023). The progressive loss of these dopaminergic terminals is the primary pathological feature of Parkinson's disease, leading to a significant reduction in striatal dopamine levels and the subsequent emergence of motor symptoms like bradykinesia, rigidity, and tremors (NIH, 2023). Therapeutic strategies targeting this population include pharmacological dopamine replacement, such as Levodopa, and dopamine receptor agonists that mimic the action of endogenous dopamine (PubMed, 2022). Modern research also focuses on regenerative medicine, including stem cell-derived dopaminergic cell transplantation and gene therapies designed to restore dopamine synthesis within the putamen (BlueRock Therapeutics, 2023). Monitoring the integrity of this population is clinically achieved through functional neuroimaging techniques like DaTscan or F-DOPA PET, which assess the density and function of these terminals (Radiopaedia, 2023). Safety concerns associated with modulating this population include the development of levodopa-induced dyskinesias and impulse control disorders due to non-physiological dopamine stimulation (Mayo Clinic, 2023).

Other names

Nigrostriatal dopaminergic terminalsPutaminal dopaminergic innervationStriatal dopamine neuronsDopaminergic projections to the putamen

Dopamine replacement, dopamine receptor agonism, inhibition of dopamine degradation, and cell replacement therapy.